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We have previously reported that a 7-d pretreatment with
hexarelin, a synthetic ligand of the GH secretagogue receptor
(GHS-R), largely prevented damages induced by ischemia and
reperfusion in isolated rat hearts. Our aim was to ascertain
whether ghrelin, an endogenous ligand of the GHS-R, is phys-
iologically endowed with cardioprotective activity. Hypoph-
ysectomized rats were treated in vivo for 7 d with either gh-
relin (320g/kg) or hexarelin (80g/kg), and their hearts were
subjected in vitro to the ischemia and reperfusion procedure.
Ghrelin was far less effective than hexarelin in preventing
increases in left ventricular end-diastolic pressure (15% and
60% protection for ghrelin and hexarelin, respectively), cor-
onary perfusion pressure (10% and 45% reduction), and re-
lease of creatine kinase in the heart perfusate (15% and 55%
reduction). In the second experiment, normal rats were pas-
sively immunized against ghrelin for 21 d before the ischemia
and reperfusion procedure. In these isolated hearts, the isch-
emia-reperfusion damage was not significantly increased
compared with control rats. After hypophysectomy, CD36
mRNA levels significantly increased, whereas those of atrial
natriuretic factor significantly decreased. We conclude that:
1) ghrelin plays a minor role in the control of heart function;
and 2) hexarelin effects are mediated in part by the GHS-R and
largely by interactions with the CD36. (Endocrinology 144:
1787–1792, 2003)
HEXARELIN IS A HIGHLY effective GH secretagogue(GHS), a family of small synthetic compounds that
exhibit potent and dose-dependent GH-releasing activity (1).
The GHSs bind to a specific G protein-coupled receptor, the
GHS-R, that is expressed in the brain and several peripheral
tissues, including the heart (2, 3). We have previously shown
that the hearts of hypophysectomized rats are more sensitive
to postischemic ventricular dysfunction, and both GH and
hexarelin, given in vivo for 1 wk, were similarly competent
in reverting the effects of GH deficiency (GHD) in hypoph-
ysectomized rats (4). Acute cardiotropic effects of hexarelin
were demonstrated also in humans (5). Demonstrations of
cardioprotective effects have also been provided for non-
peptydil GHS in rabbit and pig models (6, 7). Earlier studies
had suggested that GH plays an important role in maintain-
ing cardiovascular health, and alterations of the somato-
tropic function are frequently associated with abnormalities
of cardiac structure and function (8). Given the direct cardiac
effects of the GHSs and reversibility of cardiovascular ab-
normalities reported during GH treatment in hypopituitary
patients (9), it is also possible that long-term therapy with
GHS may be beneficial in adults with overt GHD. Recently,
a gastric-derived peptide, named ghrelin, has been proposed
as a natural ligand of the GHS-R (10). Ghrelin is endowed
with a strong stimulatory effect on GH secretion in rats and
humans (10–13), and recent studies have demonstrated that
ghrelin has acute hemodynamic effects in healthy volunteers
(14). On the basis of the foregoing, the administration of
ghrelin should be able to revert the cardiac effects of hy-
pophysectomy. Therefore, in the present study we have in-
vestigated whether ghrelin administration for 7 d might im-
prove cardiac function in hearts of hypophysectomized rats
undergoing low-flow ischemia and reperfusion in vitro to an
extent comparable to hexarelin. Moreover, to ascertain
whether ghrelin has a physiological role in the control of
cardiac function, we have measured the effects of selective
ghrelin deficiency, induced in vivo by passive immunization
for 3 wk with specific antisera, on cardiac damage induced
in vitro by ischemia-reperfusion. Finally, we have also in-
vestigated by RT-PCR whether the effects of ghrelin and
hexarelin are mediated by alteration of local synthesis of
other known cardioactive factors, such as atrial natriuretic
factor (ANF), endothelin-1 (ET-1), angiotensin-converting
enzyme (ACE), cardiotropin-1 (CT-1), adrenomedullin
(AM), and the scavenger receptor CD36.
Materials and Methods
Animals
Adult male intact and hypophysectomized Sprague Dawley rats
weighing 155–160 g (Charles River Laboratories, Inc., Calco, Como,
Italy) were housed under controlled conditions (22 2 C, 65% humidity,
and artificial light from 0600–2000 h). In the first experiment, hypoph-
ysectomized rats were randomly assigned to three experimental groups
(12 animals each) and treated sc once a day for 7 d with: 1) saline
Abbreviations: ACE, Angiotensin-converting enzyme; AM, ad-
renomedullin; ANF, atrial natriuretic factor; CK, creatine kinase; CPP,
coronary perfusion pressure; CT-1, cardiotropin-1; ET-1, endothelin-1;
GHD, GH deficiency; GHS, GH secretagogue; GHS-R, GHS receptor;
LVEDP, left ventricular end-diastolic pressure; LVDP, left ventricular-
developed pressure; LVP, left ventricular pressure; PGI2, prostacyclin.
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(1 ml/kg); 2) hexarelin (80 g/kg); or 3) ghrelin (320 g/kg). The dose
of ghrelin was chosen to be equimolar with that of hexarelin.  group
of 12 nonhypophysectomized rats were similarly treated with saline
only. All rats were killed by cervical dislocation 16 h after the last
injection. Completeness of hypophysectomy, which was performed by
the transauricolar route according to Falconi and Rossi (15), was as-
sessed by visual inspection of the sella turcica and by plasma GH
determination. Trunk blood was collected for RIA of GH concentrations,
and the hearts of six rats for each experimental group were rapidly
dissected for ischemia and reperfusion experiments, whereas the hearts
of the remaining six rats were used for total RNA extraction.
In the second experiment, normal rats were randomly assigned to two
experimental groups (six animals each) and treated ip once every other
day for 21 d with antighrelin serum (ghrelin-Ab, 0.25 ml/rat) or iso-
volumetric amounts of preimmune serum of the same rabbit (normal
rabbit serum). The polyclonal antiserum was generated against the
carboxy-terminal portion of ghrelin in rabbits and titrated as previously
described (16). All rats were killed by cervical dislocation 16 h after the
last injection. The hearts were rapidly dissected for ischemia and reper-
fusion experiments.
Hexarelin and ghrelin were synthesized by conventional solid-phase
synthesis and purified to at least 98% purity by HPLC by Neosystem
(Strasbourg, France).
All experimental protocols met the Italian Guidelines for Use of
Laboratory Animals, which conform with the European Communities
Directive of November 1986 (86/609/EEC).
Perfused heart preparations
The isolated hearts were perfused retrograde fashion through the
aorta with gassed Krebs Henseleit solution (37 C) as previously de-
scribed (17). The perfusion rate was adjusted to yield a coronary per-
fusion pressure (CPP) of 55–60 mm Hg with a flow rate of 12 ml/min.
Left ventricular pressure (LVP) was measured by inserting a small latex
balloon into the ventricular cavity and filling it with saline until left
ventricular end-diastolic pressure (LVEDP) stabilized in the range of 5
mm Hg. The preparations were electrically paced at a frequency of 300
beats/min with rectangular pulses (1 msec duration, voltage 10% above
threshold) by a Grass stimulator (model S-88, Grass Instruments,
Quincy, MA).
The hearts were allowed to stabilize for 20 min and subsequently
were exposed to the low-flow ischemia and reperfusion protocol.
Ischemia was induced by reducing the coronary flow to 2 ml/min
(CPP, 4–6 mm Hg) for a period of 40 min. At the end of this period,
reperfusion was resumed at the preischemic flow rate of 12 ml/min for
another period of 20 min. In this study, CPP and LVP were monitored
with Statham transducers (HP-1280C) connected to a dynograph (HP-
7754A, Hewlett-Packard Co., Waltham, MA). LVEDP and postischemic
left ventricular-developed pressure (LVDP, calculated as the peak LVP
minus LVEDP) were also evaluated. Furthermore, the reactivity of the
coronary vasculature to angiotensin II was evaluated to assess the in-
tegrity of endothelium-dependent relaxant mechanisms. Angiotensin II
(1 g; Sigma, St. Louis, MO) was injected as a bolus into the perfusion
system at the beginning of each experiment.
Total RNA isolation and RT-PCR assay
Total RNA was extracted from the hearts according to the single-step,
acid guanidium thiocyanate-phenol-chloroform extraction method (18).
The integrity of extracted RNA was examined by electrophoresis. Two
hundred nanograms of total RNA from each sample were subjected to
reverse transcription with Moloney murine leukemia virus reverse tran-
scriptase followed by amplification using specific primers based on the
published sequence of rat ACE, ANF, ET-1, CT-1, AM, and CD36 (Table
1). PCR analysis of total RNA yielded a DNA fragment of the expected
length for all specific mRNAs. To normalize results for differences in
RNA sampling, an aliquot of the same RT reaction was used to amplify
a rat glyceraldehyde-6-phosphate 598-bp fragment.
To assure that PCR was performed in the linear amplification range,
samples were initially analyzed after 15, 17, 20, 25, 27, 30, 35, and 40
cycles (data not shown). For each factor, we chose the cycle number that
gave half of the maximal amplification.
Enzyme and hormone assay
Completeness of hypophysectomy was determined by measuring
plasma GH concentrations using a standard double-antibody RIA and
reagents provided by the National Hormone and Pituitary Program,
National Institute of Diabetes and Digestive and Kidney Diseases, Na-
tional Institutes of Child Health & Human Development, and United
States Department of Agriculture.
Heart perfusates were collected in an iced-cooled beaker before flow
reduction and during the 20 min of reperfusion. Creatine kinase (CK)
activity and concentrations of 6-keto-PGF1 were evaluated using com-
mercially available kits (Boehringer Mannheim Italia, Milan, Italy, and
Amersham Pharmacia Biotech, Milan, Italy, respectively).
Statistical analysis
Results are expressed as the mean  sem of six determinations. Data
were analyzed for statistical significance by one-way ANOVA followed
by Tukey-Kramer test for multiple comparisons. A P value below 0.05
was considered significant.
Results
Effects of ischemia-reperfusion in hearts from
hypophysectomized rats
In the hearts from hypophysectomized rats, the values of
LVEDP gradually increased during the ischemic phase and
remained significantly more elevated than in the normal
controls (P  0.05) until the end of reperfusion (Fig. 1).
Treatment with hexarelin for 7 d largely protected the heart
of hypophysectomized rats from ischemia-reperfusion dam-
age, and at the end of the reperfusion periods LVEDP values
were not statistically different from those of control rats (Fig.
1). In contrast, heart preparations from hypophysectomized
rats given ghrelin for 7 d generated LVEDP values that were
consistently greater than the corresponding preischemic val-
ues (Fig. 1).
Similar results were obtained after calculating the LVDP
values. In fact, at the end of reperfusion, heart preparations
from control rats recovered about 50% of preischemic values,
whereas in the hypophysectomized this level was down to
only 13% (Fig. 2). Treatment with ghrelin was not really
beneficial, whereas hexarelin induced a recovery of LVP up
to values almost superimposable to those of controls (Fig. 2).
TABLE 1. Nucleotide sequence of primers used in the RT-PCR assay
Forward primer Reverse primer GenBankaccession no.
ACE GTTCGTGGAGGAGTATGACCG CCGTTGAGCTTGGCGATCTTG NM012544
ANF CAGAGAGTGAGCCGAGAC GACGAAGCCCCCATCCTA M27498
ET-1 TCTGCTGTTTGTGGCTTTCC CTGTTCCCTTGGTCTGTGGT NM012548
CT-1 CACTCTGTCCCGCCTCTT GTTACCCTTCCCTTCCCG D78591
AM TGGTTTCTCGGCTTCTCATC CGCTTGTAGTTCCCTCTTCC U15419
CD36 GGATAACATAAGCAAGGT CATAAAAGCAACAAACAT AF072411
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The level of CK activity released in the perfusates during
the 20 min of reperfusion, a biochemical marker of myocar-
dial cell lesions, was almost 3-fold higher (P  0.05) in the
heart of hypophysectomized animals compared with that of
control rats (Fig. 3). Treatment with hexarelin reduced almost
50% (P  0.05) the amount of CK released by the hearts of
hypophysectomized rats during reperfusion. In contrast,
heart preparations from hypophysectomized rats given gh-
relin generated levels of CK activity similar to those released
by hearts from saline-treated hypophysectomized rats
(Fig. 3).
Because prostacyclin (PGI2) generation plays an impor-
tant role in maintaining flow within vessels and protecting
the heart against ischemia, PGI2 release in the heart per-
fusates was measured by assaying the levels of its stable
metabolite, 6-keto-PGF1. The rate of 6-keto-PGF1 pro-
duction in hearts from hypophysectomized rats was sig-
nificantly reduced (P  0.05) in both the preischemic and
reperfusion periods compared with control rats (Fig. 4).
Treatment with hexarelin prevented this fall in the rate of
6-keto-PGF1 production during the preischemic period.
At reperfusion, the rate of formation of the eicosanoid in
hearts from hexarelin-treated hypophysectomized rats
was diminished only by 16%, and was not significantly
different from that of control rats. In contrast, in hearts
from hypophysectomized rats given ghrelin for 7 d, the
rate of formation of 6-keto-PGF1 was still reduced by 47%
in the reperfusion period (Fig. 4).
The functional integrity of the vascular endothelium
was evaluated by measuring the reactivity of the coronary
vessels to angiotensin II. The vasoconstriction induced by
angiotensin II was significantly higher in hearts of hy-
pophysectomized rats compared with those from intact
rats (Fig. 5). In fact, injection of angiotensin II into the
perfusion system of hearts from hypophysectomized sa-
line-treated rats caused a CPP rise almost 4-fold higher
(P  0.05) than that recorded in hearts from control rats
(Fig. 5). Treatment with hexarelin significantly reduced
the effect of angiotensin II in hypophysectomized rats. In
contrast, ghrelin failed to protect the vascular endothelium
from the ischemic damage (Fig. 5).
Effects of ischemia-reperfusion in hearts from rats passively
immunized against ghrelin
The induction of selective ghrelin deficiency for 3 wk had
very limited effects on cardiac performance. In fact, all he-
modynamic parameters measured in the heart of ghrelin-
Ab-treated rats undergoing the ischemia-reperfusion proce-
dure remained similar to those of rats treated with
preimmune serum (Table 2). Also, biochemical markers such
as CK release and 6-keto-PGF1 generation did not indicate
any major worsening in ghrelin-Ab-treated rats (Table 2).
Passive immunization against ghrelin did not induce any
measurable modification in basal GH plasma levels (data not
shown).
FIG. 1. LVEDP in hearts from hypophysectomized rats undergoing
ischemia-reperfusion. After an ischemia period of 40 min, hearts were
reperfused for 20 min. Hypophysectomized rats were treated in vivo
daily for 7 d with hexarelin (80 g/kg, sc), ghrelin (320 g/kg, sc), or
isovolumetric amounts of physiological saline. Intact rats served as
controls and were treated with physiological saline alone. Values of
LVEDP (mm Hg) are the mean  SEM of six hearts. The arrow indi-
cates that from time 5 min (*), all differences between hypophysec-
tomized rats and controls were statistically significant (P  0.05).
FIG. 2. LVDP. Rats were treated as described
in the legend of Fig. 1. Values of LVDP (mm
Hg) are the mean  SEM of six hearts. *, P 
0.05 vs. control.
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Effects of ghrelin and hexarelin treatment on the expression
of cardioactive factors
Hypophysectomy induced a significant reduction of ANF
cardiac mRNA levels (27%; P 0.05 vs. control) that was not
counteracted by treatment with ghrelin and hexarelin. In fact,
in hypophysectomized rats treated for 7 d with ghrelin, ANF
mRNA levels decreased by 41% compared with control, and
those treated with hexarelin decreased by 40% (Table 3; P 
0.05). The opposite pattern was determined concerning CD36
mRNA levels. In fact, hypophysectomy induced a sharp 50%
increase (P  0.05) in cardiac CD36 mRNA levels, an effect
that was only partially counteracted by ghrelin (36% in-
crease) and hexarelin (38% increase; Table 3). Hypophysec-
tomy and GHS treatment had nonsignificant effects on car-
diac mRNA levels of ACE, ET-1, CT-1, and AM (Table 3).
Discussion
In the present study, we demonstrate for the first time that
ghrelin does not have relevant roles in the physiological
regulation of cardiovascular function in the rat. In fact, the
induction of a selective ghrelin deficiency for 3 wk in normal
rats very slightly aggravated the effects of the ischemia-
reperfusion procedure on their isolated hearts. Moreover,
ghrelin administration for 7 d only minimally improved car-
diac performance in isolated hearts of hypophysectomized
rats undergoing ischemia and reperfusion. The low effec-
tiveness of ghrelin is perhaps surprising, because in the same
hypophysectomized model hexarelin displayed a very im-
portant protective effect against the ischemic damage.
It is well known that hexarelin activates a G protein-
coupled receptor, the GHS-R, which is expressed in the pi-
tuitary gland, hypothalamus, and several other nonendo-
crine tissues (2, 3). Because it has been shown that ghrelin is
a very effective ligand of the GHS-R (10), it was expected that
it could share the same cardiac activities of hexarelin. Indeed,
FIG. 3. Level of CK activity released in the perfusates. Heart perfu-
sates were collected before flow reduction and during the 20 min of
reperfusion. Treatments are described in the legend of Fig. 1. Values
of CK activity (U/20 min/g wet tissue) are the mean  SEM of six
hearts. Group 1, Control  saline; group 2, hypophysectomized 
saline; group 3, hypophysectomized  ghrelin; and group 4, hypoph-
ysectomized  hexarelin. *, P  0.05 vs. respective control  saline;
°, P  0.05 vs. hypophysectomized  saline.
FIG. 4. Rate of 6-keto-PGF1 release in the heart perfusates during
preischemia and reperfusion periods. Treatments are described in the
legend of Fig. 1. Each column represents the mean SEM of six hearts.
Group 1, Control  saline; group 2, hypophysectomized  saline;
group 3, hypophysectomized  ghrelin; and group 4, hypophysecto-
mized  hexarelin. *, P  0.05 vs. respective control; °, P  0.05 vs.
hypophysectomized  saline.
FIG. 5. Vasopressor activity of angiotensin II (1 g/bolus) injected in
paced heart preparations during preischemia. Treatments as de-
scribed in the legend of Fig. 1. Each column represents the mean 
SEM of six hearts. Group 1, Control  saline; group 2, hypophysecto-
mized  saline; group 3, hypophysectomized  ghrelin; and group 4,
hypophysectomizedhexarelin. *, P 0.05 vs. control saline; °, P
0.05 vs. hypophysectomized  saline.
TABLE 2. Effects of passive immunization against ghrelin on
hemodynamic parameters
NRS Ghrelin-Ab
LVEDP 678  52 922  83
CPP 306  37 475  58
LVDP 880  62 699  45
CK 6.72  0.71 7.66  0.84
6-Keto-PGF1 12.77  0.77 11.03  0.88
LVEDP, CPP, and LVP values are area under the curves estimated
according to the trapezoid method. LVEDP is expressed as mm Hg/60
min (ischemia  reperfusion period), CPP and LVDP as mm Hg/20
min (reperfusion period), CK as U/20 min/g wt, and 6-keto-PGF1 as
ng/min. Data are the mean SEM of six hearts for experimental group.
NRS, Normal rabbit serum.
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it has recently been shown that chronic administration of
ghrelin for 3 wk improved left ventricular dysfunction and
remodeling in rats with experimentally induced chronic
heart failure (19). However, in the latter animal model, gh-
relin effects could be mainly related to the ability of ghrelin
to stimulate the GH/IGF-I axis and, in part, to its direct
vasodilatory effects (14). In the present study, passive im-
munization against ghrelin was not followed by a decrease
of GH plasma levels, an observation not surprising when
considering that rats knock out for ghrelin showed normal
somatic growth and no significant modifications of the neu-
roendocrine axis (20). The biological activity of the polyclonal
antibody that we have used in the present research was
previously assessed by demonstrating that it was capable of
reproducibly inhibiting food intake in the rat (21).
The mechanism by which hexarelin exerts its beneficial
effects on cardiac function in hypophysectomized rats is
obviously independent of GH. Recent data demonstrate that
also in humans hexarelin increased left ventricular ejection
fraction independently of GH. In fact, acute hexarelin ad-
ministration had a positive inotropic effect in patients with
concomitant severe left ventricular dysfunction due to isch-
emic cardiomyopathy and GHD (22).
Data previously obtained by us with the tripeptide EP
51389 are consistent with this view (4). EP51389 [Aib-DTrp(2-
Me)-DTrp(2-Me)-NH2] is as effective as hexarelin in stimu-
lating GH secretion in the rat (23), but it is far less effective
in protecting the heart from ischemia (4). Interestingly, EP
51389 effectively displaced hexarelin from its hypothalamic
binding sites, but poorly from cardiac membranes (24),
which suggested the presence of multiple receptor subtypes
for GHS. More recently, evidence for the existence of GHS
receptor subtypes in rat pituitary and heart, distinct from that
previously cloned, was obtained using a photoactivable an-
alog of hexarelin (25). A few months ago, Ong and coworkers
(26) identified this cardiac binding as the CD36, a multifunc-
tional class B scavenger receptor. CD36 expression is broad
and includes many tissues, among them microvascular en-
dothelium, skeletal and smooth muscle cells, and mono-
cytes/macrophages. It has been implicated in multiple bio-
logical processes that define it as a multiligand scavenger
receptor. CD36 is involved in cellular adhesion; fatty acid
and lipid transportation, utilization, and storage; antigen
presentation; and clearance of apoptotic cells (27). An im-
portant pathological function of scavenger receptors, related
to macrophage foam cell formation and the pathogenesis of
atherosclerosis, is recognition and internalization of oxida-
tively modified low-density lipoprotein (28).
Interestingly, Ong’s research group described an unex-
pected vasoconstrictive effect elicited by hexarelin in per-
fused heart preparations (26). Hexarelin dose-dependently
increased the CPP by direct interaction with CD36 expressed
on endothelial cells of the microvasculature, but was devoid
of any effect in CD36 knockout mice and in rats genetically
deficient of CD36. This cardiovascular effect of hexarelin
appears distinct from that of ghrelin, which was reported to
decrease vascular resistance (14, 19). Thus, ghrelin and
hexarelin would have different cardiovascular effects based
mainly on their ability to bind the GHS-R (ghrelin and
hexarelin) and the CD36 (hexarelin).
Even if the discovery of hexarelin ability to bind the CD36
brings new light on its mechanism of action, many aspects
still need to be investigated further.
We have previously demonstrated that hexarelin has car-
dioprotective effects in the calcium subtraction-replenish-
ment model (calcium paradox) that were not shared by GH
(29). In fact, a 7-d in vivo administration of hexarelin induced
in perfused hearts a clear-cut inhibition of the steep ventric-
ular contracture that is the mechanical expression of calcium
paradox, whereas treatment with GH was ineffective. More-
over, hexarelin effect needed multiple exposures of the heart
to the hexapeptide, because both the in vitro direct stimula-
tion and the in vivo 3-d treatment were ineffective (29). Thus,
we argued that hexarelin was acting by modifying the func-
tional status of other cardioactive factors. For this reason, in
the present study we measured modifications of cardiac
mRNA levels after a 6-d treatment with hexarelin or ghrelin.
Our results clearly demonstrate that a large decrease in ANF
mRNA levels and, conversely, a significant increase of CD36
mRNA may be among those alterations responsible for the
increased susceptibility of hypophysectomized rats to isch-
emia-reperfusion damage. Although hexarelin and ghrelin
did not restore ANF and CD36 mRNA levels, hexarelin (but
not ghrelin) may have exerted its beneficial effects by com-
peting with oxidized long-chain fatty acids for binding on
CD36. A lower level of oxidized long-chain fatty acid may
have protected the endothelial cells of cardiac microvascu-
lature from the ischemia-reperfusion stress, thus eliciting the
better pattern of PGI2 generation and CK release observed in
hypophysectomized rats treated with hexarelin compared
with the other two hypophysectomized groups. We are con-
vinced that the ability of hexarelin to bind the CD36 is the
key, or a very important clue, to explain why this hexapep-
tide is endowed with much more pronounced cardioprotec-
tive effects compared with ghrelin and other GHS.
In conclusion, the results of this study demonstrate that
TABLE 3. Effects of ghrelin and hexarelin treatment on the mRNA levels of cardioactive factors in normal and hypophysectomized
(HYPOX) rats
Control HYPOX  saline HYPOX  ghrelin HYPOX  hexarelin
ACE 1.493  0.178 1.129  0.175 1.133  0.074 1.058  0.072
ANF 2.286  0.219 1.679  0.143a 1.339  0.226a 1.381  0.141a
ET-1 0.0442  0.0047 0.0483  0.0071 0.0450  0.0043 0.0386  0.0019
CT-1 0.899  0.058 0.999  0.122 0.972  0.093 1.049  0.050
AM 0.153  0.017 0.109  0.017 0.097  0.013 0.105  0.012
CD36 0.575  0.052 0.861  0.071a 0.781  0.043a 0.795  0.033a
Results were determined by RT-PCR and have been corrected for the relative glyceraldehyde-3-phosphate dehydrogenase value to normalize
RNA loading. Values are arbitrary units and are expressed as the mean  SEM of six hearts.
a P  0.05 vs. relative control.
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ghrelin is endowed with scarce, if any, physiological rele-
vance in the control of cardiac function. Nonetheless, other
GHS molecules, and notably hexarelin, may play important
beneficial effects in protecting the heart from ischemia-reper-
fusion damage.
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